The working paper from the Kauffman Foundation presents data regarding the nature, extent and consequences of the ‘triple helix’ of relationships between academe, the government and industry in the life and health related sciences.
The authors quantify the economic impact of introducing genetically modified (GM) crops in the research paper from Iowa State University. Short-run results suggest that it might be optimal to maintain the identity of a greater proportion of non-GM grain than is currently demanded by non-GM consumers. Long-run results show that GM crops almost always benefit society, but one scenario is presented where overall welfare falls.
The paper looks at the changing industrial structure in agricultural biotechnology, emerging research priorities and patterns, expected benefits and issues that participation and use of such technologies raise for developing countries in Asia.
An update to the 2001 report on state bioscience initiatives, the 2004 issue presents for the first time data on the size, composition and geographic distribution of biosciences throughout the 50 states along with descriptions of state initiatives.
The Milken Institute report discusses the biotechnology cluster race. The new race, according to the authors, is one that will determine where the primary geographic locations of this industry reside. The study also compares the San Diego biotechnology and life sciences cluster with 11 other clusters.
The Milken Institute report documents many of the major economic impacts of the pharmaceutical industry on the state of Illinois. According to the report, the industry directly and indirectly supports millions of jobs and pays above average-level wages to pharmaceutical industry workers.
The study from the Pew Initiative on Food and Biotechnology looks at the issues being debated in state legislature regarding genetically modified foods. A decrease was found in the number of bills intended to increase penalties for intentional crop destruction, while there was an increased number of bills intended to boost economic development through use of biotechnology.
The report from the Kauffman Foundation attempts to identify the barriers to commercialization in life sciences. The challenge, according to the report, lies in identifying and replicating the processes that facilitate swift movement of technology from the halls of academia to the front-line of American commerce and health care.
This article investigates the reasons, which led to the increasing public opposition towards agricultural biotechnology in developed and developing countries, shows how public policy and the market are responding to the increasing opposition, and presents ways for
policy-makers to handle the increasing difficulties.
The report was designed to translate the highest priority recommendations from the Phase I study, along with any new recommendations, into specific budget recommendations for the 2004 legislative session.